Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.54 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.44 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6478414 | 0.89 | MAPK14 (0.62) | MAPK14 | |
| SCHEMBL6479939 | 0.81 | MAPK14 (0.68) | MAPK14CYP2C9 | |
| SCHEMBL6490022 | 0.73 | MAPK14 (0.70) | MAPK14 | |
| SCHEMBL6492211 | 0.72 | MAPK14 (0.66) | MAPK14 | |
| SCHEMBL6490407 | 0.71 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL6803257 | 0.71 | MAPK14 (0.74) | MAPK14 | |
| SCHEMBL6478903 | 0.71 | MAPK14 (0.70) | MAPK14 | |
| SCHEMBL22589298 | 0.70 | TRPC3 (0.51) | MAPK14TRPC3TRPC7CYP2D6CYP2C9 | |
| SCHEMBL6479610 | 0.70 | MAPK14 (0.67) | MAPK14 | |
| SCHEMBL13149480 | 0.69 | CYP2D6 (0.60) | CYP2D6CYP2C9GRIN2BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790846-B2 | SUCH AS 2-ETHYOXYMETHYL-4-(4-FLOUROPHENYL)-3-PYRIDIN-4-YL-2H-ISOXAZOL-5-ONE FOR INHIBITION OF THE RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR; TREATMENT OF ARTHRITIS AND CONGESTIVE HEART FAILURE | THE PROCTER & GAMBLE COMPANY | 2004-09-14 | — | — | US | claimed |
| US-20030096814-A1 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | PROCTER & GAMBLE COMPANY, THE | 2003-05-22 | — | — | US | claimed |
| US-6919346-B2 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | THE PROCTER & GAMBLE COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-6790846-B2 | SUCH AS 2-ETHYOXYMETHYL-4-(4-FLOUROPHENYL)-3-PYRIDIN-4-YL-2H-ISOXAZOL-5-ONE FOR INHIBITION OF THE RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR; TREATMENT OF ARTHRITIS AND CONGESTIVE HEART FAILURE | THE PROCTER & GAMBLE COMPANY | 2004-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096814-A1 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | TNF, IL5, GPR35 | MAPK14 1280/4885TRPC3 4731/4885TRPC7 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.